Biosimilar Candidates

Formycon Development Pipeline

Formycon currently has five biosimilar candidates in development. In addition to the pembrolizumab biosimilar candidate FYB206 and the dupilumab biosimilar candidate FYB208, these include the three undisclosed biosimilar candidates FYB209, FYB210 and FYB286.